-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Achieves a New Milestone in Oral-Formulation Exports: First Shipment of 8 Million Tablets of Antipyretic and Analgesic Drugs Sold to Africa
Category:
发布时间：2025-03-26
【概要描述】
With the arrival of spring, all things are bursting into life. On March 25, a container loaded with 8 million acetaminophen tablets stood ready for shipment in front of the automated warehouse at Shijiazhuang Sihua Pharmaceutical Group in the Shijiazhuang High-tech Industrial Development Zone, soon to be dispatched to the African market. “This large-scale export of oral dosage forms marks a new breakthrough in our pharmaceutical formulation export business,” said Li Bo, General Manager of the Sihua Formulation Foreign Trade Center, visibly excited as he inspected the logistics operations on site.
Spring has returned to the land, and all things are thriving. On March 25, in front of the automated warehouse of Shijiazhuang Sihua Pharmaceutical Group in the Shijiazhuang High-tech Industrial Development Zone, a container loaded with 8 million acetaminophen tablets was fully prepared for shipment and would soon be dispatched to the African market. “This large-scale export of oral dosage-form products marks a new breakthrough in our pharmaceutical formulation export business,” said the person on site. Li Bo, General Manager of the Four-Drug Preparations Foreign Trade Center, said excitedly as he inspected the logistics operations.
As a leading domestic manufacturer of large-volume parenteral solutions, after more than two decades of operation, Sihua Pharmaceutical’s export business now spans five continents, with its products reaching 100 countries and regions. The company has maintained double-digit annual growth in export volume, firmly securing the top position in the industry.
“Foreign trade operations must adopt a ‘two-pronged’ approach: while injectable products have long enjoyed a strong export reputation, we must also keep pace with the export of oral formulations. Accelerating the transition from ‘product export’ to ‘brand export’ and achieving a breakthrough in the export of oral formulations have been the longstanding goals of Sihua Pharmaceutical,” said Li Bo, who has been involved in foreign trade for more than 20 years.
“Breaking through the barriers to ‘going global’ with formulated products depends not only on well-established foreign-trade channels, but even more on robust product portfolios and reliable quality and technology support. It is precisely the international standards of Shijiazhuang No. 4 Pharmaceutical’s products that African customers value most.” Speaking about the new developments in the company’s exports, Li Bo said, “Our accumulated innovation achievements and the continuous expansion of our international certifications provide strong assurance for accelerating our entry into global markets. In recent years, from the steady growth in the scale of infusion product exports to the increasing diversity of formulated-product categories, these advances have been largely driven by our increased investment in R&D and our accelerated digital and intelligent transformation. It is precisely the resulting product and cost advantages that have opened up vast room for development in our international operations.”
According to available information, in 2024, Sihua Pharmaceutical secured approval for 82 new products, including 61 dosage forms, with oral solid dosage forms accounting for more than half of the total. The company’s R&D submissions and approvals rank among the highest in the domestic industry. In the first quarter of this year alone, 15 new products received approval, sustaining its leading momentum and driving a remarkable transformation in its product portfolio toward high-end injectables and greater formulation diversity. Meanwhile, last year the group successively obtained registration certificates for 47 products in 19 countries, including the United Arab Emirates and Costa Rica, bringing its total number of product registrations to 435. It has also passed quality certifications and official audits in more than 10 countries, such as the Philippines and Peru. Today, Sihua Pharmaceutical’s robust and comprehensive product portfolio is powerfully supporting market development both domestically and internationally.
“By leveraging international trade fairs and other platforms, we are proactively gathering intelligence on overseas market demand, engaging in global market cooperation, and continuously enhancing our brand’s international visibility and influence, thereby steadily expanding our network of international business partners,” said Li Bo. He added that, using this large-scale export of oral pharmaceutical products to Africa as a strategic entry point, the company will accelerate the development of a diversified global market network. Moving forward, the company will further identify additional high-potential product categories for overseas markets, strive to elevate more “China’s Best Medicines—Made in Shijiazhuang” brands on the world stage, and drive a transformative shift in its foreign trade operations—from “volume-based exports” to “value-driven exports.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091